A235980 Stock Overview
A drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MedPacto, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,450.00 |
| 52 Week High | ₩17,240.00 |
| 52 Week Low | ₩6,110.00 |
| Beta | 0.80 |
| 11 Month Change | -6.76% |
| 3 Month Change | -20.32% |
| 1 Year Change | -49.35% |
| 33 Year Change | -88.14% |
| 5 Year Change | n/a |
| Change since IPO | -58.50% |
Recent News & Updates
Companies Like MedPacto (KOSDAQ:235980) Are In A Position To Invest In Growth
Aug 05
MedPacto (KOSDAQ:235980) Is In A Good Position To Deliver On Growth Plans
Mar 28Shareholder Returns
| A235980 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -10.7% | -1.2% | -2.1% |
| 1Y | -49.4% | 28.3% | 0.3% |
Return vs Industry: A235980 underperformed the KR Biotechs industry which returned 28.3% over the past year.
Return vs Market: A235980 underperformed the KR Market which returned 0.3% over the past year.
Price Volatility
| A235980 volatility | |
|---|---|
| A235980 Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.2% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A235980's share price has been volatile over the past 3 months.
Volatility Over Time: A235980's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 62 | Seong-Jin Kim | www.medpacto.com |
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.
MedPacto, Inc. Fundamentals Summary
| A235980 fundamental statistics | |
|---|---|
| Market cap | ₩250.18b |
| Earnings (TTM) | -₩30.63b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.2x
P/E RatioIs A235980 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A235980 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩30.63b |
| Earnings | -₩30.63b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -912.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did A235980 perform over the long term?
See historical performance and comparison